EDRN Study

On July 5, 2005, PreMD announced a collaborative research agreement with the National Cancer Institute’s EDRN to include ColorectAlert™ in a major colorectal cancer clinical trial. Details of the trial include:

• ColorectAlert™ will be included in a 600-patient, multi-center, prospective cross-sectional cohort validation trial examining FOBT, stool genetic tests and other markers for colorectal cancer;
• The NCI is a sponsor of this study, which is the first validation trial conducted by the EDRN, along with other industrial co-sponsors; and
• The trial, which will be conducted at various sites, is to be led by the GLNE CEC Consortium, which consists of the University of Michigan, the Dana Farber Cancer Institute, Dartmouth Medical School and St. Michael’s Hospital in Toronto, Ontario. The University of Texas M.D. Anderson Cancer Center will also participate.

The clinical trial will include three categories of patients: those diagnosed with cancer; those with polyps; and those with no disease. The study will examine the ability of multiple markers to identify the presence of cancer alone and in combination. Patients will be tested at baseline and then following treatment in cases where treatment is required.